IMMUNICUM
Immunicum is a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology.
IMMUNICUM
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2002-01-01
Address:
Gothenburg, Vastra Gotaland, Sweden
Country:
Sweden
Website Url:
http://www.immunicum.se
Total Employee:
11+
Status:
Active
Contact:
(463)141-5052
Email Addresses:
[email protected]
Total Funding:
54.6 M USD
Technology used in webpage:
SPF Euro Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Japanese Yen Google Maps For Work Barracuda Networks IP-Only Sweden
Similar Organizations
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.immunicum.se
- Host name: redirect1-1.ilait.se
- IP address: 62.109.34.30
- Location: Sölvesborg Sweden
- Latitude: 56.0521
- Longitude: 14.5753
- Timezone: Europe/Stockholm
- Postal: 294 32
More informations about "Immunicum"
Immunicum - Crunchbase Company Profile & Funding
Immunicum is a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of …See details»
Immunicum addresses essential challenges in cancer therapy
Immunicum AB: Immunicum Announces Corporate Rebranding …
Jun 23, 2022 Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell …See details»
Mendus – Wikipedia
Mendus, tidigare Immunicum AB, är ett svenskt-nederländskt börsnoterat biotekniskt forskningsföretag med forskningslaboratorium i Leiden i Nederländerna. Det grundades 2002 och arbetar inom området "allogen dendritcellsbiologi" (allogen= "härstammande från annan individ av samma art" . Dess aktier handlas på Stockholmsbörsen. Immunicum grundades i Sverige 2002 som en avknoppning från Sahlgrenska UniversitetssjukhusetSee details»
Immunicum AB: Immunicum Announces Corporate Rebranding …
Immunicum AB: Immunicum Announces Corporate Rebranding and Name Change to Mendus ABSee details»
Immunicum and DCprime combining forces - Amazon Web Services
Nov 19, 2020 • Immunicum to acquire all outstanding shares of DCprime • Merger to Establish Leader in Cell-Based Cancer Immunotherapies Merger • Erik Manting, PhD, will join the …See details»
Immunicum changes name to Mendus - BioStock
Jul 1, 2022 The Swedish Companies Registration Office has approved Immunicum’s name change, and the company is now known as Mendus. Since June 27, the company has been …See details»
Immunicum - The Org
Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Industries. Biotechnology. …See details»
20210412 Immunicum Annual Report Publication FINAL ENG
Immunicum AB (publ)| Östermalmstorg 5, 114 42 Stockholm| Tel +46 87328 400| Orgnr. 556629-1786|immunicum.se Press Release 12 April 2021 Immunicum AB (publ) Publishes the Annual …See details»
Immunicum Company Profile - Office Locations, Competitors, …
Oct 29, 2024 Immunicum is a biopharmaceutical company that develops immune therapies against a range of various tumors. The Company's lead product, ilixadencel, has been …See details»
Immunicum announces corporate rebranding and …
Jun 23, 2022 Initiated with the merger and integration of Immunicum and DCprime and accelerated by subsequent directional pipeline decisions and promising novel R&D initiatives, these developments have resulted in a multi …See details»
Immunicum - businessabc.net
Feb 25, 2025 Immunicum is a clinical-stage biopharmaceutical company developing a unique approach to activate the body’s own ability to fight cancer. History Immunicum was founded in …See details»
Immunicum – del av Sveriges långsiktiga satsning på ATMP
Feb 2, 2021 Immunicum befinner sig i en framskriden klinisk utvecklingsfas medan start up-bolaget Asgard Therapeutics är i preklinisk fas. Immunicum AB grundades 2002 av en …See details»
Immunicum - Funding, Financials, Valuation & Investors
Immunicum is a clinical phase II company, develops cancer immunotherapies. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. …See details»
BioStock Studio: Immunicum’s CEO on the company’s new …
Sep 13, 2021 Swedish immunotherapy company Immunicum has broadened its cancer treatment focus with the addition of drug candidate DCP-001 thanks to the merger with Dutch …See details»
Immunicum — Primed for value appreciation - Edison Group
Sep 14, 2021 Following the transformational merger with DCprime in December 2020, Immunicum now aims to become a global leader in off-the-shelf, allogeneic cell therapies, …See details»
Cederquist advises Immunicum in connection with share issue
Jun 18, 2021 Cederquist has advised Immunicum AB in connection with a directed share issue to selected Swedish and international institutional investors. Immunicum is leveraging its …See details»
Immunicum AB: Immunicum Announces Corporate Rebranding …
Jun 23, 2022 Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell …See details»
Immunicum’s vision for the cancer therapy landscape - BioStock
Nov 3, 2021 Two of the biggest challenges in oncology are hard-to-treat solid tumours and tumour recurrence. Swedish biotech Immunicum are on a mission to tackle both challenges …See details»
Immunicum continues cell therapy trials after positive kidney …
Sep 26, 2019 Sweden’s Immunicum has announced detailed results from its mid-stage trial of its oncology cell-based immunotherapy ilixadencel, which it says justify further clinical trials after …See details»